The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.
Merck & Co. Inc. has jumped on the merger and acquisitions merry-go-round to snap up Australia's Viralytics Ltd. and broaden its research efforts in oncolytic virus therapy.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Arbele has emerged as a global leader in the Cadherin 17 area, not only in clinical progress but also for its “secret recipe” for application in T-cell engagers, its CEO tells Scrip.
The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
